key: cord-0927941-pu65285c
authors: Yong, Celina M.; Spinelli, Kateri J.; Chiu, Shih Ting; Jones, Brandon; Penny, Brian; Gummidipundi, Santosh; Beach, Shire; Perino, Alex; Turakhia, Mintu; Heidenreich, Paul; Gluckman, Ty J.
title: Cardiovascular Procedural Deferral and Outcomes over COVID-19 Pandemic Phases: A Multi-Center Study
date: 2021-06-26
journal: Am Heart J
DOI: 10.1016/j.ahj.2021.06.011
sha: 156bc3d508d67ea99b71693c797a8ab06ff0e6ed
doc_id: 927941
cord_uid: pu65285c

BACKGROUND: The COVID-19 pandemic has disrupted routine cardiovascular care, with unclear impact on procedural deferrals and associated outcomes across diverse patient populations. METHODS: Cardiovascular procedures performed at 30 hospitals across six Western states in two large, non-profit healthcare systems (Providence St. Joseph Health and Stanford Healthcare) from December 2018-June 2020 were analyzed for changes over time. Risk-adjusted in-hospital mortality was compared across pandemic phases with multivariate logistic regression. RESULTS: Among 36,125 procedures (69% percutaneous coronary intervention, 13% coronary artery bypass graft surgery, 10% transcatheter aortic valve replacement, and 8% surgical aortic valve replacement), weekly volumes changed in two distinct phases after the initial inflection point on February 23, 2020: an initial period of significant deferral (COVID I: March 15 to April 11) followed by recovery (COVID II: April 12 onwards). Compared to pre-COVID, COVID I patients were less likely to be female (p=0.0003), older (p<0.0001), Asian or Black (p=0.02), or Medicare insured (p<0.0001), and COVID I procedures were higher acuity (p<0.0001), but not higher complexity. In COVID II, there was a trend towards more procedural deferral in regions with a higher COVID-19 burden (p=0.05). Compared to pre-COVID, there were no differences in risk-adjusted in-hospital mortality during both COVID phases. CONCLUSIONS: Significant decreases in cardiovascular procedural volumes occurred early in the COVID-19 pandemic, with disproportionate impacts by race, gender, and age. These findings should inform our approach to future healthcare disruptions.

In 2020, rapid spread of the novel coronavirus (SARS-CoV-2) 1 forced hospitals across the world to triage medical procedures in an effort to flatten the COVID-19 growth curve. In mid-March of 2020, shelter-in-place orders were instituted across the United States. Professional society guidelines 2 and federal mandates 3, 4 recommended deferral of non-urgent procedures at scale, both to conserve resources and to prevent patients from unnecessary risk of exposure to the virus 5 . Many cardiovascular procedures were postponed, permitting only those performed on an urgent basis, with unclear impact on diverse patient populations.

Understanding how large-scale procedural deferral was implemented across patient populations and whether any associated adverse outcomes occurred is vital to strategizing our approach to care delivery with future major healthcare disruptions. In this multi-center study, we examined changes in cardiovascular procedural volumes; changes in patient demographics, acuity, and complexity of procedures; relationships between procedure deferral and local COVID-19 burden; and patient outcomes over time for both percutaneous and open treatment of coronary artery and aortic valve disease. were included in this study. Data from PSJH were obtained from the Microsoft Azure cloud data warehouse, which pulls data from the EPIC and MEDITECH electronic health record systems that are in use across all PSJH hospitals. Data from SHC were obtained from the STAnford Research Repository (STARR) platform, which pulls data from the EPIC electronic Tables I and II ). This study was approved by the PSJH Institutional Review Board and the Stanford University Institutional Review Board, with waiver of informed consent.

The primary outcome was change in weekly volume of procedures (aggregate, and for each individual procedure: PCI, CABG surgery, TAVR, and SAVR) before and after the pandemic In-hospital mortality was obtained by either date of death prior to discharge or discharge status as expired.

Categorical data are presented as frequencies (percentages). Numerical data are presented as mean (SD) or median (interquartile range [IQR]), as appropriate. Income quartiles and education categories were calculated based on a patient's zip code from U.S. Census data. The Great Circle Distance formula 6 was used to calculate distance from a patient's home to the nearest hospital in the study, using latitude and longitude associated with each zip code. Longdistance travel was defined as farther than the 3 rd quartile of the distance distribution (31 miles).

COVID-19 case burden was obtained by matching facility zip codes to corresponding publicly available, county-level COVID-19 data and calculating mean COVID-19 cases for each county according to relevant date ranges normalized to county population 7 . Multivariable logistic regression was performed to evaluate mortality, with adjustment for demographic variables including age, sex, race, ethnicity, state, distance from hospital, income quartile, education, insurance type, inpatient/outpatient status, as well as baseline comorbidities listed in Table I . To account for potential hospital variation, we also evaluated patient outcomes by taking hospital as a random effect in a mixed model.

For procedural complexity and mortality analyses, combination procedures were reassigned to one of the four primary procedure categories based on clinical likelihood of the -culprit‖ procedure. For example, we assigned mortality from a combined TAVR/SAVR procedure to the TAVR category as we assumed that TAVR was the initial (primary) procedure and SAVR was subsequently required for complication. PCI/CABG surgery combination procedures were assigned to the PCI category. SAVR procedures involving CABG surgery or PCI were assigned to the SAVR category.

To understand the magnitude of procedural deferral, we identified the first inflection point and nadir by fitting the weekly case rates over time using loss functions to smooth the time series curve. The time break points and slopes were then defined using segmented regression. To understand differences in clinical demographics and outcomes of patients who had their procedure during peak COVID-19 deferral, we chose a 4-week period surrounding the nadir (March 29, 2020) for all procedures combined, with COVID I defined as March 15, 2020 to April 11, 2020 . The beginning of the COVID I period also corresponded to the release of federal mandates and professional society recommendations for procedural deferral. We defined pre-COVID as all dates from December 2018 until COVID I, and COVID II as all dates after COVID I, respectively. Trends among the three COVID-19 periods were compared using univariate χ 2 , Fisher exact, or Kruskal-Wallis tests for each variable, as appropriate.

Percentage change in procedural volume during the different phases was calculated as the relative difference in mean weekly volume for each period divided by the mean weekly volume during the pre-COVID period. There was a 0.5-3% missing rate for race, ethnicity, income, education, distance from nearest hospital, and insurance. P-values <0.05 were considered statistically significant for primary comparisons. For sub-group analyses, lower p-values were considered statistically significant to account for Bonferroni adjustment for multiple comparisons. SAS (7.1) and R statistical programs were used for all analyses.

From December 2, 2018 to June 28, 2020, we identified 36,152 unique cardiovascular procedures (69% PCI, 13% CABG surgery, 10% TAVR and 8% SAVR) at 30 hospitals across six states. These procedures involved 33,058 unique patients, of whom 8% had more than one procedure during the 20-month timeframe.

For all procedures combined, weekly volumes reached a nadir on March 29, 2020 ( Figure IA) .

Following the initial inflection on February 23, 2020, procedures decreased at a rate of -21 cases per week, from a pre-COVID weekly volume of 465 (95% CI 452, 478) down to a nadir weekly volume of 210, corresponding to a mean weekly volume during COVID I of 264 (95% CI 143, 385) and a 43% reduction from the pre-COVID period (Supplemental Table III ). After the second inflection point (March 29, 2020), procedures increased at a rate of +15 cases per

week to a peak weekly volume of 431 (May 10, 2020), corresponding to a mean weekly volume during COVID II of 359 (95% CI 305, 414, p<0.0001) and a 23% reduction from the pre-COVID period. Analysis by each procedure type revealed that PCI, CABG surgery, and TAVR had largely consistent volumes leading up to the pandemic ( Figure IB) . A brief drop in aortic valve procedures was noted during the 2018 and 2019 winter holiday periods along with a gradual decline in overall SAVR volumes over the entire pre-COVID period. Analysis of statistical inflection points unique to each procedure revealed that PCI and TAVR volumes started to decline as early as the week of February 16, 2020. Whereas CABG surgery volumes started to decline slightly later on March 1, 2020, no significant inflection points were found for SAVR. For PCI, CABG surgery, and TAVR, the appreciable decrease in procedural volume found during COVID I was followed by active recovery of cases during COVID II.

Patient demographics varied significantly by COVID phase (Table I, Figure II ). Compared to pre-COVID, patients in COVID I (n=1056) were less likely to be older (median 67 [IQR 59-76] vs pre-COVID 69 [IQR 61-77], p<0.0001), female (23% vs. pre-COVID 28%, p=0.0003) and

Black or Asian (2.0% and 3.9% respectively vs. pre-COVID 2.5% and 5.6% respectively, p=0.02 for all races). The proportion with Medicare insurance also dropped from 60% pre-COVID to 53% during COVID I, before returning to 60% in COVID II. In contrast, there was an increase in the proportion of patients in COVID I who had low income/Medicaid, government, or private insurance (9.3%, 4.5%, 31% respectively vs. pre-COVID 8.2%, 2.8%, 26% respectively, p<0.0001 across all insurance types). Baseline comorbidities did not change significantly over the study period, except for heart failure, which increased in prevalence from pre-COVID to COVID I, followed by a slight decrease in COVID II (35% to 38% to 37% respectively, p=0.001).

Sub-group analysis of patient demographic changes between time periods for each of the four procedural categories showed similar trends as above (Supplemental Table IV ). After Bonferroni adjustment for multiple comparisons, the only additional significant finding was a decrease in the proportion undergoing PCI as an outpatient from pre-COVID to COVID-I, with a return to baseline during COVID II (35% to 29% to 35% respectively, p=0.002).

During COVID I, there was no significant correlation between local COVID-19 case burden and changes in procedural volume (correlation coefficient -0.27, p=0.16 for COVID I).

During COVID II, however, there was a trend towards decreased procedural volumes in areas with higher COVID-19 case rates (correlation coefficient -0.36, p-value=0.054 for COVID II, Table V) .

For those undergoing PCI, the acuity of indication changed by COVID phase (p<0.0001 across all indications, Figure IV ). Compared to pre-COVID, the proportion with STEMI during COVID I increased from 21% to 28%, before decreasing down to 23% during COVID II. The proportion presenting with NSTE-ACS increased by a small amount from pre-COVID to COVID I (39% to 42%), with a decrease in those presenting with SIHD during the same time frame (19% to 14%).

For aortic stenosis procedures, non-significant trends in procedural complexity across COVID phases were observed (p=0.18 for TAVR and p=0.9 for SAVR, Figure V ). Compared to pre-COVID, patients undergoing TAVR during COVID I were more likely to be coded as having -with MCC‖ for their MS-DRG (48% to 55%). In contrast, patients undergoing SAVR saw a decrease in this over the same time frame (46% to 42%). No trends in procedural complexity were found for patients undergoing coronary revascularization.

Compared to pre-COVID, there were no significant differences in in-hospital mortality during COVID I or II for any of the four procedures, both before and after risk adjustment ( Figure VI ).

There was, however, a strong trend towards a higher mortality rate after CABG surgery in COVID I compared to pre-COVID (adjusted OR 2.61 [95% CI 0.98, 6.93]). Based on this, and as part of a sensitivity analysis, we analyzed mortality using the statistically-derived inflection point dates (redefining COVID I as the four week period starting on the first inflection point date), and found a statistically higher mortality rate after CABG surgery during COVID I, both before and after risk adjustment ( [IQR 4.8-9.9] days), with a near return to baseline in COVID II (median 7.2 [IQR 5.3-10] days, p=0.01). There were no significant changes in LOS among the other procedure types.

We report findings from a large, multi-center study that evaluated cardiovascular procedural volumes and outcomes during early periods of the COVID-19 pandemic among diverse patient populations in the United States. Important observations include a significant decline in procedural volume that began on February 23, 2020, reaching a nadir on March 29, 2020; this was followed by a partial recovery. It is noteworthy that by using statistical analysis to define the inflection point, procedural deferrals were noted to predate national mandates. Second, we observed changes in patient demographics for those treated during COVID I, including differences by age, sex, race, and insurance type. Third, despite increased acuity of procedural indication during COVID I, no significant changes in risk-adjusted in-hospital mortality were observed.

While the first case of COVID-19 in the United States was identified in February 2020, it was not until mid-March of 2020 that the American College of Cardiology and Society of Angiography and Intervention published a consensus statement regarding deferral of cardiovascular procedures, occurring in tandem with release of federal mandates and shelter-inplace orders [2] [3] [4] . Our data suggest that procedural volumes actually began to decline before formal implementation of these policies, by as much as one month. While a prior study from England noted a decline in procedural volumes from March through May 2020, continuous volume curves were not evaluated 8 . It is unclear the degree to which early deferrals in our study were driven by declining patient demand versus a curtailed supply by physicians, though prior studies demonstrating significant drops in presentations for acute conditions during the pandemic suggest that patients may have started to avoid hospital-based procedures even before physicians and policymakers were formally deferring them 5, [9] [10] [11] .

Interestingly, SAVR volumes in our study appeared to be the exception, with a gradual decline in volume over time that was unaltered by the COVID-19 pandemic. With the rise in TAVR volumes over the last decade partially supplanting a portion of SAVR procedures 12, 13 , it is speculative that the patients referred for SAVR may have had specific treatment indications that required timely intervention, impervious to outside forces. A small study of aortic stenosis patients receiving treatment in Switzerland during the pandemic showed that none of their patients received SAVR during the March-April, 2020 period, and all were directed to either expedited or deferred TAVR 14 . In the setting of severe resource constraints, it is possible that aortic stenosis patients who might normally be offered both treatment options might be steered towards the less invasive one, in hopes of minimizing time in the hospital.

Investigation into the changing demographics of patients who were treated during different phases of COVID-19 suggest either prioritization or self-selection of certain patient populations for procedural treatment during the COVID I period. The finding that COVID I patients were both younger and less likely to have Medicare insurance is consistent with suspected reluctance by older patients to seek care given early data suggesting a higher COVID-19 mortality in this population 15 . Beyond this, however, we also found a decrease in the proportion of Blacks and Asians treated during the COVID I period. Among potential drivers, we know that resource constraints during the pandemic resulted in longer door-toballoon times, with discussion about treating COVID-19 STEMI patients with a fibrinolyticfirst rather than primary PCI strategy 16, 17 . With a higher burden of COVID-19 among racial/ethnic minorities 18 , changes in treatment strategies might have also impacted this group more. Social, financial, and environmental strains from the pandemic, as well as misinformation, may also have disproportionately impacted vulnerable populations, resulting in greater barriers to seeking timely care.

Based on our analysis of the relationship between procedural deferral and local COVID-19 burden, we discovered a slight trend towards an association between the two during COVID II, but not COVID I. This suggests that deferral during COVID I may have followed mandates irrespective of local COVID-19 burden, but that once this acute period was over, hospitals may have started to variably resume care based on severity of local COVID-19 conditions. Interestingly, findings during the COVID I period in New York City did show that high density COVID-19 counties experienced more procedural deferral than low density counties 19 .

Combined with our data, this suggests that perhaps a certain threshold is necessary before local COVID-19 burden directly impacts procedural deferrals (which were not reached on the West Coast during COVID I). Further studies to distinguish the degree to which deferral was driven by patients, clinicians, or facilities will be vital to inform plans in a post-COVID-19 era and in the event of future major healthcare disruptions. If patient fears are the primary driver of the reduction in procedures, as some early data has suggested 20-23 , then strong patient and public education efforts will be critical to ensuring that patients overcome concerns about coming to the hospital for treatment of their cardiovascular disease.

Notable changes in procedural volume by COVID-19 phase raise the question of what kinds of indications and procedure types were prioritized during these periods. The fact that STEMI comprised a larger proportion of indications for PCI during COVID I is consistent with stated national goals of performing only urgent, life-saving procedures at that time. Importantly, with resumption of procedures in COVID II, we sought to answer the question of whether the first patients to be prioritized would be a second tier of very sick patients who had their procedure deferred during COVID I 24 , or whether they would mirror the pre-COVID population. Our findings suggest that the patients who received procedures in COVID II had less acute indications compared to those in COVID I, but still slightly greater acuity than that noted in the pre-COVID period. The trends of increased procedural complexity for TAVR with simultaneous decreased complexity for SAVR during COVID I also raise the possibility that some aortic stenosis patients who might have normally been treated with SAVR were directed to a less invasive alternative due to pandemic constraints, at the expense of increased procedural complexity.

It is reassuring that despite increasing acuity and complexity of procedures during COVID I, we found no significant differences in risk-adjusted in-hospital mortality. The fact that patient outcomes remained unchanged during the worst phases of the pandemic goes a long way to helping patients rebuild the confidence to resume care as the pandemic continues. Our data support findings from a meta-analysis that showed no difference in mortality after STEMI despite increased door-to-balloon times during the pandemic 25 . However, our sensitivity analysis of mortality (based on statistically-derived inflection point dates) did show a higher risk-adjusted mortality rate after CABG surgery, raising concern that subtle changes in outcomes may have actually occurred depending on the exact dates studied. One possible explanation is that even before formal policy changes were implemented in mid-March 2020, low-risk surgical candidates may have already anticipated the COVID-19 surge and decided to defer their own treatment early, leaving only higher-risk, higher-complexity patients to be treated. This may not have been mirrored among percutaneous procedural candidates due to the minimally invasive nature of those procedures. In theory, risk adjustment should have accounted for these differences, but we recognize that the pandemic may have also changed the way that healthcare was delivered. For example, one possibility is that the quality of treatment during this period may have suffered, with many staff reassigned to other COVID-19-related duties. It is promising that despite the known significant risks of deferring treatment for severe aortic stenosis, 26, 27 our data suggests that patients and clinicians were able to prioritize those most in need of a procedure without a change in short-term mortality. Only time will tell, however, whether there are long-term impacts from these delays.

Whereas the unchanged length of stay during COVID I may be representative of efforts to minimize time in the hospital, the decreased length of stay during COVID II is likely reflective of patients with lower acuity and complexity. These findings differ slightly from a single center study showing shorter lengths of stay for all cardiovascular admissions, but these were not uniquely focused on those related to procedures 5 . Our findings of a lower proportion of outpatient procedures performed in COVID I confirm that patients being treated during this time were predominantly non-elective cases.

This study has several limitations. While our dataset is largely limited to the Western United States, the diversity within our sample suggests high likelihood of applicability to other states, albeit with differences in phase dating. Even though we adjusted for multiple patient characteristics and comorbidities, additional (and potentially unrecognized) confounders may still exist. For example, we adjusted for long-distance travel, but we recognize that the significance of distance in miles may differ in rural and urban areas. In addition, while we assigned one primary procedure as the culprit for mortality based on clinical likelihood, it is possible that other scenarios may have taken place. Importantly, our use of ICD-10 and MS- 19 DRG codes is subject to coding-related limitations and we were unable to collect certain clinical and procedural details, including echocardiographic data. We also assumed that patients did not switch out of hospitals or healthcare systems during the study period. Finally, we did not capture out of hospital deaths or mortality over a longer time horizon.

The COVID-19 pandemic has produced an unprecedented natural experiment, allowing assessment of broad procedural deferral at scale. While the full impact may not be realized for years, our evaluation helps to inform ongoing responses to the pandemic, as well as future strategies to address workforce disruptions and abrupt changes in operational capacity or funding. Importantly, our findings related to vulnerable populations also serve as a harbinger of widening health disparities beyond COVID-19, reinforcing the importance of thoughtful strategies to minimize the indirect toll of the pandemic. 

Changes in indication between time periods were statistically significant (p<0.0001). Table 1 were included in the riskadjusted mortality models. 

Public Health Response to the Initiation and Spread of Pandemic COVID-19 in the United States

American College of Cardiology's Interventional Council and the Society for Cardiovascular Angiography and Interventions. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC's Interventional Council and SCAI

COVID-19 Response Plan. Veterans Health Administration -Office of Emergency Management

Centers for Disease Control and Prevention

Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic

Calculate distance and bearing between two Latitude/Longitude points using haversine formula in JavaScript

nytimes/covid-19-data. The New York Times

Impact of COVID-19 on cardiac procedure activity in England and associated 30-day mortality

Case Rates, Treatment Approaches, and Outcomes in Acute Myocardial Infarction During the Coronavirus Disease 2019 Pandemic

The Covid-19 Pandemic and the Incidence of Acute Myocardial Infarction

The COVID-19 Pandemic and Acute Aortic Dissections in New York

Utilization and 1-Year Mortality for Transcatheter Aortic Valve Replacement and Surgical Aortic Valve Replacement in New York Patients With Aortic Stenosis

Trends in volume and risk profiles of patients undergoing isolated surgical and transcatheter aortic valve replacement

Characteristics and Outcomes of Patients Deferred for Transcatheter Aortic Valve Replacement Because of COVID-19

COVID-19) -United States

Impact of COVID-19 pandemic on STEMI care: An expanded analysis from the United States

Impact of COVID-19 on percutaneous coronary intervention for ST-elevation myocardial infarction

Racial Disparities in Incidence and Outcomes Among Patients With COVID-19

Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction Before and During COVID in New York

Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic

Characteristics Associated With Out-of-Hospital Cardiac Arrests and Resuscitations During the Novel Coronavirus Disease

Società Italiana di Cardiologia and the CCU Academy investigators group. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era

Society for Cardiovascular Angiography and Interventions (SCAI) and the

American College of Cardiology (ACC) Interventional Council. Cardiac procedural deferral during the coronavirus (COVID-19) pandemic

Mortality, Stroke, and Hospitalization Associated With Deferred vs Expedited Aortic Valve Replacement in Patients Referred for Symptomatic Severe Aortic Stenosis During the COVID-19 Pandemic

Effect of the COVID-19 pandemic on mortality of patients with STEMI: a systematic review and meta-analysis

Mortality while waiting for aortic valve replacement

cerebrovascular disease, MI = myocardial infarction, PAD = peripheral artery disease, PCI = percutaneous coronary intervention, Q = quarter, SAVR = surgical aortic valve replacement